COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05004181

Not reported

Not reported

2021-08-13

Not recruiting

nonRCT

Non-randomized

Parallel

Open label

multi-center

Prevention

inclusion criteria: have given informed consent by signing the informed consent form (icf) before initiation of any trial-specific procedures. volunteers who at the time of consent are: part a: 18 to 55 years old. part b and part c: 18 to 85 years old (~60% should be 18 to 55 years old and ~40% 56 to 85 years old). for cohorts 1 to 5: in part a, who have received bnt162b2 vaccine (30 µg, two-dose regimen) in either a clinical trial or as part of the governmental vaccination programs at least 6 months before visit 0. participants who are currently enrolled in the phase iii bnt162-02 / c4591001 trial, have already been unblinded, and have previously received two doses of bnt162b2 at least 6 months earlier can be included (for cohorts 1 and 4 in part b, prior enrollment and dosing in the bnt162-02 / c4591001 trial is mandatory). at enrollment into part b of this trial, their participation in the bnt162-02 / c4591001 trial will be terminated. participants should have not experienced covid-19 based on medical history. for cohort 6: are covid-19 vaccine-naïve and have not experienced covid-19 based on their medical history. are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other trial procedures. are overall healthy at visit 0 in the clinical judgment of the investigator based on the medical history, clinical assessment (including physical examination, vital signs, blood and urine clinical laboratory tests, 12-lead electrocardiogram (ecg), and oral swab for nucleic acid amplification-based test (naat)-based severe acute respiratory syndrome coronavirus 2 (sars-cov-2) testing). note: healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 12 weeks before visit 0, can be included. note: volunteers who had hepatitis c (hcv) infection, but have completed curative treatment based on the medical history can be included. volunteers who had or have hepatitis b (hbv) or human immunodeficiency virus (hiv) based on the medical history cannot be included. agree not to enroll in another trial of an investigational medicinal product (imp), starting after visit 0 and continuously until the last planned visit in this trial. women of childbearing potential (wocbp) must test negative in a urine beta-human chorionic gonadotropin (β-hcg) test at visits 0 and 1. wocbp must agree to practice a highly effective form of contraception starting at visit 0 and continuously until 28 days after their last imp administration in this trial. wocbp must confirm that they practiced an acceptable form of contraception for the 14 days prior to visit 0. wocbp must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction starting after visit 0 and continuously until 28 days after their last imp injection in this trial. men who are sexually active with a wocbp and have not had a vasectomy must agree to use a highly effective form of contraception with their female partner of childbearing potential starting after visit 0 and continuously until 28 days after their last imp injection in this trial. men must be willing to refrain from sperm donation, starting after visit 0 and continuously until 28 days after their last vaccination. for part c, cohorts 7, 8, and 9: have received two or three documented doses of any authorized covid-19 rna-based vaccine (e.g., bnt162b2 [comirnaty] or the moderna vaccine [spikevax]) prior to being diagnosed with sars-cov-2 infection from january 2022 onwards (and limited to a period when there was a high prevalence of sars-cov-2 omicron infections). note: the interval between the last covid-19 rna-based vaccine administered and randomization should be >4 months. the latest prior diagnosed sars-cov-2 infection should be at least 2 months before randomization. the latest sars-cov-2 infection should be documented with a result from a naat (as a preferable option). in case no historic naat result is available proving prior sars-cov-2 infection, the local positive result of sars-cov-2 n-binding antibodies done at screening will be sufficient.

any existing condition which may affect vaccine injection and/or assessment of local reactions assessment, e.g., tattoos, severe scars, etc. any bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that, in the investigator's judgment, make the participant inappropriate for the trial. any current febrile illness (body temperature ≥38.0°c/≥100.4°f) or other acute illness within 48 h prior to day 1/imp injection in this trial. any current or history of cardiovascular diseases, e.g., myocarditis, pericarditis, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias. history of covid-19 and/or clinical (based on covid-19 symptoms/signs alone, if a sars cov 2 naat result was not available) or microbiological (based on covid-19 symptoms/signs and a positive sars cov 2 naat result) evidence of prior infection with sars cov 2 at screening (visit 0). note: not applicable for part c. history of guillain-barré syndrome. known or suspected immunodeficiency. history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the trial imps. history or known allergy, hypersensitivity, or intolerance to the trial imp including any excipients of the imps in this trial. have received any sars cov 2 vaccination other than bnt162b2 (30 µg bnt162b2 given as a course of two doses approximately 21 days apart). note: not applicable for part c. have received a live or live attenuated vaccine within 28 days prior to day 1/imp injection. have received any other vaccines within 14 days before or after any imp injection, e.g., influenza, tetanus, pneumococcal, hepatitis a or b. when possible standard or care vaccinations should be planned with the trial imp administrations in mind. individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout this trial. inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. receipt of blood/plasma products or immunoglobulin, from 60 days before imp administration or planned receipt throughout this trial. participation in other trials involving imp within 28 days or 5 half-lives (whichever is longer) prior to visit 1 and/or during trial participation, besides participation in trials with bnt162b2. are pregnant or breastfeeding or are planning pregnancy within 28 days after last imp treatment. are vulnerable individuals as per international conference on harmonisation (ich) e6 definition, i.e., are individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. for part c, cohorts 7, 8, and 9: vaccination with other non-rna or unauthorized covid-19 vaccines. for part c, cohorts 7, 8, and 9: vaccination with any covid-19 vaccine after sars-cov-2 infection from january 2022 onwards (and limited to a period when there was a high prevalence of sars-cov-2 omicron infections).

12

BioNTech SE

18

85

Germany;South Africa;Turkey;United States

Healthy volunteers

N/A

1383

All parts - Percentage of participants reporting local reactions at the injection site;All parts - Percentage of participants reporting serious adverse events (SAEs);All parts - Percentage of participants reporting systemic events;Part A and C - Percentage of participants reporting adverse events (AEs);Part B - Geometric mean ratio (GMR) of B.1.1.7;Part B - GMR of B.1.1.7 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - GMR of B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - GMR of B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - GMR of B.1.617.2 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - Percentage of participants reporting adverse events (AEs);Part B - The difference in Seroresponse (SR) to B.1.1.7;Part B - The difference in SR to B.1.1.7 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - The difference in SR to B.1.617.2;Part B - The difference in SR to B.1.617.2 NT 1 month after 1 dose of BNT162b2 (B.1.617.2) on BNT162b2-experienced participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02 / C4591001 trial;Part B - The difference in SR to B.1.617.2 NT 1 month after 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) on BNT162b2-naïve participants to the reference strain NT 1 month after 2 doses of BNT162b2 in participants from the Phase III BNT162-02/C4591001 trial;Part C - GMR of B.1.1.529 NT 1 month after one dose of BNT162b2 (B.1.1.529) in RNA-based COVID-19 vaccine-experienced participants with history of SARS-CoV-2 infection to those at 1 month after one dose of BNT162b2 for Cohorts 7 and 8.;Part C - The difference in SR of B.1.1.529 NT 1 month after one dose of BNT162b2 (B.1.1.529) in RNA-based COVID-19 vaccine-experienced participants with history of SARS-CoV-2 infection to those at 1 month after one dose of BNT162b2 for Cohorts 7 and 8.

None

Phase 2

[{"arm_notes": "1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1 dose of BNT162b2 (B.1.1.7) of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1 dose of BNT162b2 (B.1.617.2) of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1 dose of BNT162b2 of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 \u00b5g ", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "part B 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 \u00b5g", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "part B 1 dose of BNT162b2 (B.1.617.2) of 30 \u00b5g ", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "part B 3 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 \u00b5g ", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part C 1 dose of BNT162b2 (B.1.1.529) of 30 \u00b5g ", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Part C 1 dose of BNT162b2 of 30 \u00b5g ", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "no vaccination within 3 months after Visit 1 ", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]